Abstract: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.

Abstract: Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R1 represents an optionally substituted C1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR5; R2 represents —(C?O)—R6, —CHR6R7, or —CH2OR8; and R3 and R4, which may be identical or different, each represent an amino group, an azide group, or —X—R9, with the proviso that any one of R3 and R4 is an amino group).

Abstract: Provided is a compound which is useful as a prophylactic or therapeutic agent for various diseases in which T-type calcium channels are involved, such as hypertension, arrhythmia, pain and cancers, the compound having antagonistic activity against T-type calcium channels, being highly stable in the body and having low risk of, for example, genotoxicity. Disclosed is a compound represented by the following general formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein R1 represents —NH(C?O)—V—R3 or —(C?O)NH—V—R3; V represents a single bond, methylene, or —C(CH3)2O—; R2 represents a optionally substituted C1-6 alkyl group; X represents a hydrogen atom, an oxygen atom, a hydroxyl group, a methyl group, or a methylene group; A represents —NR6—, —O—CH2—, or —S—CH2—; n represents the number of methylene chains and represents an integer of 0, 1 or 2; and a doublet containing a dotted line represents a single bond or a double bond.

Abstract: Provided is a compound which is useful as a prophylactic or therapeutic agent for various diseases in which T-type calcium channels are involved, such as hypertension, arrhythmia, pain and cancers, the compound having antagonistic activity against T-type calcium channels, being highly stable in the body and having low risk of, for example, genotoxicity. Disclosed is a compound represented by the following general formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein R1 represents —NH(C?O)—V—R3 or —(C?O)NH—V—R3; V represents a single bond, methylene, or —C(CH3)2O—; R2 represents a optionally substituted C1-6 alkyl group; X represents a hydrogen atom, an oxygen atom, a hydroxyl group, a methyl group, or a methylene group; A represents —NR6—, —O—CH2—, or —S—CH2—; n represents the number of methylene chains and represents an integer of 0, 1 or 2; and a doublet containing a dotted line represents a single bond or a double bond.

Abstract: Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R1 represents an optionally substituted C1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR5; R2 represents —(C?O)—R6, —CHR6R7, or —CH2OR8; and R3 and R4, which may be identical or different, each represent an amino group, an azide group, or —X—R9, with the proviso that any one of R3 and R4 is an amino group).

Abstract: Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product. A compound represented by general formula (I), and a pharmaceutical agent containing the same, are disclosed: wherein n represents the number of nitrogen atoms contained in the 6-membered fused aromatic ring, and is 0, 1 or 2; p represents the number of nitrogen atoms contained in the 6-membered aromatic ring, and is 0 or 1; X represents an oxygen atom, —SO2— or —N(R9)—; and R1 to R5 each represents a hydrogen atom or other substituents.

Abstract: Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product. A compound represented by general formula (I), and a pharmaceutical agent containing the same, are disclosed: wherein n represents the number of nitrogen atoms contained in the 6-membered fused aromatic ring, and is 0, 1 or 2; p represents the number of nitrogen atoms contained in the 6-membered aromatic ring, and is 0 or 1; X represents an oxygen atom, —SO2— or —N(R9)—; and R1 to R5 each represents a hydrogen atom or other substituents.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.